2269 N'un PE Oranı emsallerine kıyasla nasıldır?

2269 N, Price-To-Earnings değerine göre iyi bir değerdir. Eş ortalamaya (13.7x) kıyasla oran (34.8x).

2269 N'nin PE Oranı, Global Life Sciences Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

2269 N Price-To-Earnings Oranı ( 13.7 x) baz alındığında, Global Life Sciences sektör ortalamasına ( 33.6 x) kıyasla iyi bir değerdir.

2269 N'nin PE Oranı, Adil PE Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PE Oranıdır.

Değerleme analizi için 2269 N 'in Price-To-Earnings Adil Oranını hesaplamak için yeterli veri yok.

Gelecekteki nakit akışlarına bakıldığında 2269 N 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

2269 N ( MX$62.53 ) [[adil değer]] tahminimizin altında işlem görüyor ( MX$130.21 )

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Fiyat tahminini göstermek için yeterli veri yok.

WuXi Biologics (Cayman) (BMV:2269 N) - Hisse Senedi Fiyatı, Haberler ve Analizler

2269 N Stoklara Genel Bakış

An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. Daha fazla detay

2269 N temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	3/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 52% daha düşük bir oranda işlem görüyor

Kazançların yılda 17.12% oranında artması öngörülüyor

Kazançlar geçen yıl 1.7% oranında arttı

Risk Analizi

Hisse senetleri oldukça likit değildir

WuXi Biologics (Cayman) Inc. Rakipler

Medpace Holdings

NasdaqGS:MEDP

US$9.8b

Bruker

NasdaqGS:BRKR

US$7.3b

Pharmaron Beijing

SZSE:300759

CN¥46.3b

Hangzhou Tigermed Consulting

SZSE:300347

CN¥52.2b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti WuXi Biologics (Cayman)
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$62.53
52 Haftanın En Yüksek Seviyesi	HK$62.53
52 Haftanın En Düşük Seviyesi	HK$62.53
Beta	0.66
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	n/a
33 Yıllık Değişim	-74.45%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-73.63%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	2269 N	MX Life Sciences	MX Pazar
7D	0%	0%	0%
1Y	n/a	0%	0%

Getiri vs. Endüstri: 2269 N un MX Life Sciences sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: 2269 N un MX Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is 2269 N's price volatile compared to industry and market?
2269 N volatility
2269 N Average Weekly Movement	n/a
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

İstikrarlı Hisse Senedi Fiyatı: 2269 N son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 2269 N 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	12,397	Chris Chen	www.wuxibiologics.com

WuXi Biologics (Cayman) Inc. Temel Bilgiler Özeti

WuXi Biologics (Cayman)'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
2269 N temel i̇stati̇sti̇kler
Piyasa değeri	Mex$132.67b
Kazançlar(TTM)	Mex$9.71b
Gelir(TTM)	Mex$38.71b

13.7x

F/K Oranı

3.4x

P/S Oranı

2269 N aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
2269 N gelir tablosu (TTM)
Gelir	CN¥16.55b
Gelir Maliyeti	CN¥9.68b
Brüt Kâr	CN¥6.87b
Diğer Giderler	CN¥2.72b
Kazançlar	CN¥4.15b

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

Mar 26, 2024

Hisse başına kazanç (EPS)	0.99
Brüt Marj	41.51%
Net Kâr Marjı	25.08%
Borç/Özkaynak Oranı	7.7%

2269 N uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

2269 N Stoklara Genel Bakış

Ödüller

Risk Analizi

WuXi Biologics (Cayman) Inc. Rakipler

NasdaqGS:MEDP

US$9.8b

NasdaqGS:BRKR

US$7.3b

SZSE:300759

CN¥46.3b

SZSE:300347

CN¥52.2b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Investor sentiment deteriorates as stock falls 26%

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Less than half of directors are independent

CEO & Executive Director recently sold Mex$45m worth of stock

Investor sentiment improved over the past week

Less than half of directors are independent

Less than half of directors are independent

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

CEO & Executive Director recently bought Mex$102m worth of stock

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

CEO & Executive Director recently sold Mex$88m worth of stock

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019)

Insider recently bought Mex$9.2m worth of stock

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019)

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group.

WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Executive VP recently sold Mex$275m worth of stock

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform